Antibody-drug conjugate · Cytotoxic, directed at folate receptor alpha (FOLR1) · developed by Sutro Biopharma
Luveltamab tazevibulin is an antibody-drug conjugate in which an IgG1 antibody (SP8166) binds folate receptor alpha (FOLR1) on tumor cells. After internalization and cleavage of its linker, the released hemiasterlin warhead SC209 inhibits tubulin polymerization, causing mitotic arrest and cell death. It is being studied in ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05870748 | Phase 2/3 | Ovarian Cancer | Terminated | STRO |
| NCT06238687 | Phase 1/2 | Neoplasm Malignant | Completed | STRO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Epithelial Ovarian CancerFallopian Tube CancerNeoplasm MalignantOvarian CancerPlatinum-resistant Ovarian CancerPrimary Peritoneal Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the STRO page.
See STRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
STRO catalysts and pipeline →